ClearMed
CardiologyRandomized Clinical Trial5 min read

Individualized Cardiac Index-Guided Hemodynamic Therapy in High-Risk Patients Undergoing Elective Major Abdominal Surgery: The PELICAN Randomized Clinical Trial

The date of last follow-up was January 15, 2026.

Published in JAMARandomized controlled trial
5/5 Gold Standard
Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

Source

Study Cohort

1128 patients

Among high-risk patients undergoing elective major abdominal surgery, individualized cardiac index-guided hemodynamic therapy targeting the patient's preoperative resting cardiac index did not reduce the incidence of a composite outcome of acute kidney injury, acute myocardial injury, severe infectious complications, nonfatal cardiac arrest, or death within the first 7 postoperative days compared with routine hemodynamic therapy.

What Changes?

Cardiology · Randomized Clinical Trial

Current Standard

Conventional cardiology practice relies on standard-of-care monitoring and existing regimens prior to this .

New Finding

This multicenter, single-blind, superiority randomized clinical trial enrolled high-risk patients undergoing elective major abdominal surgery between October 8, 2023, and October 25, 2025, at 12 university medical centers in Austria, the Czech Republic, Denmark, Germany, and Spain.

3 Key Takeaways

Plain English Summary
  1. 01Core Finding

    Secondary outcomes included the individual components of the primary outcome within the first 7 postoperative days.

  2. 02Study Evidence

    Tested in a (1128 patients) at the randomized clinical trial stage.

  3. 03Practical Meaning

    Controlled trial findings show causal benefit under protocol rules; real-world effectiveness can vary across patients.

What This Means for You

Among high-risk patients undergoing elective major abdominal surgery, individualized cardiac index-guided hemodynamic therapy targeting the patient's preoperative resting cardiac index did not reduce the incidence of a composite outcome of acute kidney injury, acute myocardial injury, severe infectious complications, nonfatal cardiac arrest, or death within the first 7 postoperative days compared with routine hemodynamic therapy.

The Discovery

It remains unclear if intraoperative hemodynamic therapy should be guided by cardiac index. To evaluate whether individualized cardiac index-guided hemodynamic therapy vs routine hemodynamic therapy improves outcomes in high-risk patients undergoing elective major abdominal surgery. This multicenter, single-blind, superiority randomized clinical trial enrolled high-risk patients undergoing elective major abdominal surgery between October 8, 2023, and October 25, 2025, at 12 university medical centers in Austria, the Czech Republic, Denmark, Germany, and Spain. The date of last follow-up was January 15, 2026. Patients were randomized to individualized cardiac index-guided hemodynamic therapy targeting the patient's preoperative resting cardiac index vs routine hemodynamic therapy (with blinded cardiac index monitoring). The primary outcome was a composite of acute kidney injury, acute myocardial injury, severe infectious complications, nonfatal cardiac arrest, or death within the first 7 postoperative days. Secondary outcomes included the individual components of the primary outcome within the first 7 postoperative days. The primary outcome was a composite of acute kidney injury, acute myocardial injury, severe infectious complications, nonfatal cardiac arrest, or death within the first 7 postoperative days. Secondary outcomes included the individual components of the primary outcome within the first 7 postoperative days. Of the 1128 patients enrolled, 1111 were randomized and 1095 were included in the primary analysis (median age, 67 years [IQR, 59-74 years]; 49.4% were female). The primary outcome occurred in 243 of 549 patients (44.3%) in the individualized cardiac index-guided hemodynamic therapy group vs 256 of 546 patients (46.9%) in the routine hemodynamic therapy group (relative risk, 0.94 [95.1% CI, 0.83-1.08]; P = .38). There were no between-group differences for the incidence of the individual components of the primary outcome within the first 7 postoperative days.

How It Works, Simply

This cardiology research focuses on cardiovascular hemodynamic & lipid pathway modulation. Researchers evaluated it using a randomized controlled trial (1128 patients) at the randomized clinical trial stage of medical research.

3 Key Takeaways

Clinical Takeaways
  1. 01Core Finding

    Secondary outcomes included the individual components of the primary outcome within the first 7 postoperative days.

  2. 02Study Evidence

    Tested in a (1128 patients) at the randomized clinical trial stage.

  3. 03Practical Meaning

    Controlled trial findings show causal benefit under protocol rules; real-world effectiveness can vary across patients.

01

Biological Mechanism & Study Design

Study Design & Cohort

Randomized controlled trial

Randomized controlled trial (1128 patients) · Randomized Clinical Trial

Biological Pathway & Modality

Cardiovascular hemodynamic & lipid pathway modulation

Intervention: Individualized Cardiac Index-Guided Hemodynamic Therapy

02

Experimental Findings & Endpoints

It remains unclear if intraoperative hemodynamic therapy should be guided by cardiac index.

To evaluate whether individualized cardiac index-guided hemodynamic therapy vs routine hemodynamic therapy improves outcomes in high-risk patients undergoing elective major abdominal surgery. This multicenter, single-blind, superiority randomized clinical trial enrolled high-risk patients undergoing elective major abdominal surgery between October 8, 2023, and October 25, 2025, at 12 university medical centers in Austria, the Czech Republic, Denmark, Germany, and Spain.

The date of last follow-up was January 15, 2026. Patients were randomized to individualized cardiac index-guided hemodynamic therapy targeting the patient's preoperative resting cardiac index vs routine hemodynamic therapy (with blinded cardiac index monitoring).

The primary outcome was a composite of acute kidney injury, acute myocardial injury, severe infectious complications, nonfatal cardiac arrest, or death within the first 7 postoperative days. Secondary outcomes included the individual components of the primary outcome within the first 7 postoperative days.

The primary outcome was a composite of acute kidney injury, acute myocardial injury, severe infectious complications, nonfatal cardiac arrest, or death within the first 7 postoperative days. Secondary outcomes included the individual components of the primary outcome within the first 7 postoperative days.

Of the 1128 patients enrolled, 1111 were randomized and 1095 were included in the primary analysis (median age, 67 years [IQR, 59-74 years]; 49.4% were female). The primary outcome occurred in 243 of 549 patients (44.3%) in the individualized cardiac index-guided hemodynamic therapy group vs 256 of 546 patients (46.9%) in the routine hemodynamic therapy group (relative risk, 0.94 [95.1% CI, 0.83-1.08]; P = .38).

There were no between-group differences for the incidence of the individual components of the primary outcome within the first 7 postoperative days.

03

Clinical Translation & Practice Context

Among high-risk patients undergoing elective major abdominal surgery, individualized cardiac index-guided hemodynamic therapy targeting the patient's preoperative resting cardiac index did not reduce the incidence of a composite outcome of acute kidney injury, acute myocardial injury, severe infectious complications, nonfatal cardiac arrest, or death within the first 7 postoperative days compared with routine hemodynamic therapy.

03

The Bottom Line · Clinical Pearl

“Among high-risk patients undergoing elective major abdominal surgery, individualized cardiac index-guided hemodynamic therapy targeting the patient's preoperative resting cardiac index did not reduce the incidence of a composite outcome of acute kidney injury, acute myocardial injury, severe infectious complications, nonfatal cardiac arrest, or death within the first 7 postoperative days compared with routine hemodynamic therapy.”

Published in JAMA · Current Stage: Randomized Clinical Trial

Cardiology · Randomized Clinical Trial
Study Type
Randomized controlled trial

Randomized controlled trial (1128 patients)

Evidence Score
5/5 · Gold-Standard Human Evidence
Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

Who It Applies To
High-Risk Patients Undergoing Elective Major Abdominal Surgery: The PELICAN Randomized C
Intervention & Mechanism
Individualized Cardiac Index-Guided Hemodynamic Therapy

Cardiovascular hemodynamic & lipid pathway modulation

Key Limitation
Controlled trial findings show causal benefit under protocol rules; real-world effectiveness can vary across patients.

Translational Stage

LEVEL 1 · Randomized Clinical Trial

Classified as Randomized controlled trial along the clinical evidence continuum

  1. Lab & Discovery
  2. Early Trials
  3. 3Randomized Clinical TrialActive
  4. 4Meta & Practice

Original Publication & AMA Citation

Individualized Cardiac Index-Guided Hemodynamic Therapy in High-Risk Patients Undergoing Elective Major Abdominal Surgery: The PELICAN Randomized Clinical Trial. JAMA. Published 2026;Oct 19. Accessed November 15, 2026. https://pubmed.ncbi.nlm.nih.gov/42896534/

JAMA

https://pubmed.ncbi.nlm.nih.gov/42896534/

Read Original Paper

Continue Reading

Related in Cardiology

View all Cardiology briefings →
CARDIOLOGY · CLINICAL PRACTICE

AI Identifies Hidden Heart Signal for Sudden Death Risk

AI can uncover subtle cardiac risks in routine scans, improving sudden death prediction. This discovery could enable earlier identification of thousands at risk for sudden cardiac death, allowing for timely interventions.

3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDaily
CARDIOLOGY · CLINICAL PRACTICE

Senior Statins: Short-Term Safety, Long-Term Questions

While stopping statins after 70 might initially seem safe for those without prior heart events, the long-term risks suggest a careful discussion with your doctor is essential. For years, the medical community has debated the optimal duration of statin therapy, especially as patients enter advanced age.

3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDaily
Cardiology editorial photograph for Dietary Protein Source Linked to Testosterone Levels in Men
CARDIOLOGY · CLINICAL PRACTICE

Dietary Protein Source Linked to Testosterone Levels in Men

For men, the source of dietary protein—animal (especially dairy) versus plant—appears to correlate with significant differences in circulating testosterone levels, suggesting a potential modifiable lifestyle factor. Currently, dietary interventions specifically differentiating between animal and plant protein for modulating testosterone levels are not a standard component of clinical practice beyond general healthy eating guidelines.

3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDaily